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signiﬁcantly less susceptible to protease inhibitors (PIs) than the subtype B reference strain, NL4-3; therefore,
themechanism of how AE-Gag62 reduced viral drug susceptibility to PIs was studied in this report. The results
showed that the lysine residue at amino acid position 165 (K165) of AE-Gag62 played a role in reducing the
drug susceptibility of the recombinant virus to PIs. In addition, K165 potentially appears more frequently in
CRF01_AE viruses than in the viruses of othermajor HIV-1 subtypes. Although K165 had no effect on the extent
of recombinant protease-mediated in vitro Gag cleavage, it enhanced the incorporation of the Gag–Pol
precursor protein, p160, into virions. Taken together, these results suggest that K165 of CRF01_AE Gag affects
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Human immunodeﬁciency virus type 1 (HIV-1) is characterized by
extensive genetic heterogeneity (Gaschen et al., 2002). Due to this
variability, HIV-1 is subdivided into three groups, M (major), O
(outlying) and N (new or non-M, non-O). The viruses in group M,
which are responsible for the majority of infections in the worldwide
HIV-1 epidemic, are further classiﬁed into many subtypes and
circulating recombinant forms (CRFs). While subtype B of HIV-1 is the
predominant subtype in the Americas, Europe and Australia, a growing
epidemic of non-B subtypes is found in Africa and Asia (Hemelaar et al.,
2006; McCutchan, 2006). CRF01_AE is one of the major HIV-1 subtypes
that dominate the global epidemic, and is prevalent throughout
Southeast Asia (Hemelaar et al., 2006; McCutchan, 2006). In particular,
this subtype is responsible for more than 95% of infection cases in
Thailand, Cambodia and Vietnam (Hemelaar et al., 2006).Protease (PR) inhibitors (PIs) were designed against subtype B
viruses, but are believed to retain their activity against other
subtypes; however, only limited data are presently available as to
how viral diversity among different subtypes and CRFs affects drug
susceptibility and resistance. In addition, although the amino acid
sequence of HIV-1 Gag is relatively conserved, a certain level of amino
acid variability is observed in Gag p17, p2, p7 and p6 regions of non-B
and B subtype viruses (Bally et al., 2000; Barrie et al., 1996; de Oliveira
et al., 2003; Gilbert et al., 2005; Marlowe et al., 2004). Several reports
show that amino acid substitutions in HIV-1 Gag affect the drug
susceptibility of PR or the level of viral ﬁtness (Carrillo et al., 1998;
Cote et al., 2001; Doyon et al., 1996; Gatanaga et al., 2002; Ho et al.,
2008; Kaufmann et al., 2001; Mammano et al., 1998; Myint et al.,
2004; Tamiya et al., 2004; Zhang et al., 1997); thus, it is conceivable
that the amino acid variations found in Gag of non-B subtypes
potentially affect the drug susceptibility or catalytic efﬁciency of PR.
We recently studied the drug susceptibility of recombinant viruses
containing CRF01_AE Gag (AE-Gag), and found that AE-Gag reduced
the drug susceptibility of recombinant viruses to the currently
available PIs (Jinnopat et al., 2009). In particular, the PI susceptibility
of the recombinant virus containing the AE-Gag derived from plasma
sample #62, AE-Gag62, was signiﬁcantly reduced compared to the
reference subtype B strain. In this report, we examined the
mechanism of how AE-Gag62 reduced viral drug susceptibility to PIs.
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N-terminal regions of AE-Gag62 play a role in reducing the drug
susceptibility of the recombinant virus to several PIs
Drug susceptibility tests revealed that the recombinant virus contain-
ingAE-Gag62was signiﬁcantly less susceptible to9 currently available PIs,
amprenavir (APV), atazanavir sulfate (ATV), darunavir (DRV), indinavir
sulfate (IDV), lopinavir (LPV), nelﬁnavir (NFV), ritonavir (RTV), saquinavir
(SQV) and tiprenavir (TPV), than NL4-3 (Adachi et al., 1986)-derived
luciferase reporter virus, NL-Luc,whichwas used as the reference subtype
B strain in this study (compare Figs. 1A and B). In order to estimate the
region of AE-Gag62 responsible for reducing viral drug susceptibility, we
ﬁrst constructed recombinant viruses containing N-terminal (p17 and a
partial sequence of p24, designated as AE-Gag62N) and C-terminal
(a partial sequence of p24, p2, p7, p1 and p6; designated as AE-Gag62C)
regions of AE-Gag62, and subjected them to drug susceptibility tests. The
results showed that the recombinant virus containing AE-Gag62N was
less susceptible to 6 PIs than the reference subtype B strain (compare
Figs. 1A and C). In contrast, the drug susceptibility of the recombinant
virus containingAE-Gag62C toPIswas similar to or ratherhigher than that
of the reference subtype B strain (compare Figs. 1A and D). These results
suggested that N-terminal regions of AE-Gag62 contained regions which
play a role in reducing viral drug susceptibility to PIs. The effect of AE-
Gag62N on reducing viral drug susceptibility was not as strong as that ofFig. 1. N-terminal regions of AE-Gag62 play a role in reducing viral drug susceptibility to PI
(C) and AE-Gag62C (D), as well as of reference subtype B strain (A), to 9 currently availabl
recombinant gag constructs are shown above the panels. Results are expressed as fold change
used in drug susceptibility tests are indicated below the panels in chronological order accord
SQV, RTV, IDV, NFV, APV, LPV, ATV, TPV and DRV. Results are presented as the means and s
performed within a one-way analysis of variance experimental design, and N2.0- or b0.5-fold
In addition, the mean IC50 values with standard deviations of PIs for suppressing the replicfull-length AE-Gag62 (compare Figs. 1B and C), whereas AE-Gag62C
showed no signiﬁcant effect on viral drug susceptibility (Fig. 1D). These
results indicated that AE-Gag62 partially lost its activity in reducing viral
drug susceptibility by fragmentation. There is a possibility thatAE-Gag62C
cooperates with AE-Gag62N to reduce viral drug susceptibility to PIs.
Another possibility is that chimeric Gag protein, consisting of partial
fragments of NL4-3 Gag and AE-Gag62, probably had a different protein
conformation relative to full-length AE-Gag62; thus, it eventually lost
partial activity in reducing viral drug susceptibility. Nevertheless, AE-
Gag62N reduced the drug susceptibility of the recombinant virus to 6 PIs
(Fig. 1C); thus, we further examined the region of AE-Gag62N that was
responsible for reducing viral drug susceptibility to PIs. It is noteworthy
that the antiviral effect of SQV, TPV and DRV was not altered by AE-
Gag62N, while that of the 6 remaining PIs, RTV, IDV, NFV, APV, LPV and
ATV, was signiﬁcantly reduced by AE-Gag62N (Fig. 1C), suggesting that
the 9 PIs may be classiﬁed into 2 groups by their sensitivity to the amino
acid variation of Gag.
AE-Gag62N contains additional mutations relative to other AE-Gag
Wenext compared the deduced amino acid sequence of Gag among
NL4-3 and 5 AE-Gag, including a reference CRF01_AE strain, CM240. As
a result, we found 5 additional mutations in AE-Gag62N relative to
other AE-Gag examined (Fig. 2, arrowheads). Namely, AE-Gag62N
contained amino acid substitutions, D14E [amino acid substitutions. Drug susceptibility of the recombinant viruses containing AE-Gag62 (B), AE-Gag62N
e PIs was examined, as described in Materials and methods. Schematic illustrations of
in susceptibility to PI relative to the reference subtype B virus (fold resistance). Nine PIs
ing to the approval date from the United States Food and Drug Administration (US FDA):
tandard deviations (error bars) of four independent experiments. Dunnett's t test was
change in susceptibility to the PI, with a P value of b0.05, was considered signiﬁcant (*).
ation of recombinant viruses are shown in Supplementary Table 1.
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K110E and S165K, as compared to NL4-3 Gag (Fig. 2, arrowhead). In
order to examine whether these mutations affect viral drug suscep-
tibility to PIs, we next constructed a series of AE-Gag62N-derived
mutants containing a point mutation. The amino acid residue at
position 165 of Gag was serine (S165) in NL4-3 Gag, while asparagine
(N165) in all AE-Gag examined, except AE-Gag62 (Fig. 2); thus, we
prepared 5 recombinant viruses containing AE-Gag62N-derived
mutants, AE-Gag62N-E14D, AE-Gag62N-R91K/I92V, AE-Gag62N-
E110K, AE-Gag62N-K165N and AE-Gag62N-K165S.The lysine residue at amino acid position 165 of AE-Gag62 plays a role in
reducing viral drug susceptibility to PIs
Five recombinant viruses containing AE-Gag62N-derived mutants
were subjected to drug susceptibility tests. The results showed that 3
recombinant viruses containing AE-Gag62N-E14D, AE-Gag62N-K91R/
V92I and AE-Gag62N-E110K showed similar drug susceptibility to the
parental AE-Gag62N-recombinant virus (compare Figs. 1C and 3A). In
contrast, the drug susceptibility of 2 recombinant viruses containingFig. 2. Deduced amino acid sequences of AE-Gag. Amino acid sequences of 5 AE-Gag, includin
and p6 regions are denoted in the ﬁgure. In addition, the position of PstI recognition site was
is shown above the aligned sequence. Dots denote amino acid identity, while dashes r
substitutions found in N-terminal regions (before PstI recognition site) of AE-Gag62, but noAE-Gag62N-K165N and AE-Gag62N-K165S was equivalent to the
reference subtype B strain (compare Figs. 1A and 3A). These results
suggested that the lysine residue at amino acid position 165 (K165) of
AE-Gag62N plays a role in reducing the drug susceptibility of the AE-
Gag62N-recombinant virus to PIs. In order to conﬁrm the role of K165
in viral drug susceptibility, we next introduced amino acid substitu-
tions, K165N and K165S, into full-length AE-Gag62, and subjected the
recombinant viruses containing these AE-Gag62-derived mutants to
drug susceptibility tests. The results showed that 2 recombinant
viruses containing AE-Gag62-K165N and AE-Gag62-K165S were
signiﬁcantly more susceptible to PIs than parental AE-Gag62-
recombinant virus (compare Figs. 1B and 3B). These results suggested
that K165 played an important role in reducing the drug susceptibility
of AE-Gag62-recombinant virus to PIs.Comparison of the amino acid residue at position 165 of Gag among
major HIV-1 subtypes
N165 or K165 was detected in the AE-Gag examined, while S165
was detected in NL4-3 Gag (Fig. 2). Thus, we next examined the aminog CM240 Gag, were aligned with that of NL4-3 Gag. Positions of Gag p17, p24, p2, p7, p1
indicated. Numbering of amino acid residues is based on the sequence of NL4-3 Gag, and
epresent gaps introduced to optimize alignment. Arrowheads represent amino acid
t in that of other AE-Gag.
Fig. 3. Drug susceptibility of recombinant viruses containing AE-Gag62N- and AE-Gag62-derived mutants. Drug susceptibility of recombinant viruses containing AE-Gag62N- (A)
and AE-Gag62-derived mutants (B) to 9 PIs was evaluated, as described in the ﬁgure legend for Fig. 1. IDs of AE-Gagmutants and 9 PIs used in the tests are indicated above and below
the panels, respectively. Results are presented as the means and standard deviations (error bars) of four independent experiments. Dunnett's t test was performedwithin a one-way
analysis of variance experimental design, and N2.0- or b0.5-fold change in susceptibility to the PI, with a P value of b0.05, was considered signiﬁcant (*). In addition, the mean IC50
values with standard deviations of PIs for suppressing the replication of recombinant viruses are shown in Supplementary Table 1.
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purpose, we retrieved the nucleotide sequences of HIV-1 gene
fragments encoding Gag p24 of 6 major HIV-1 subtypes from the
HIV-1 sequence database (http://www.hiv.lanl.gov/). We then
compared the amino acid residue at position 165 of Gag, and the
results showed that approximately 80% of subtypes A and D viruses
contained S165, while approximately 20% contained N165 (Table 1).
In addition, most (N98%) subtype B and C viruses as well as CRF02_AG
viruses contained S165 (Table 1). In stark contract, 98.5% of CRF01_AE
viruses contained N165, while 1% of those viruses contained K165. The
amino acid substitution, N165K (change of genetic code from aac/aat
to aaa) probably occurs more frequently than substitution S165K
(agc/agt to aaa); thus, it is suggested that K165 potentially appears
more frequently in CRF01_AE viruses than in other major HIV-1
subtypes.K165 plays a role in reducing the drug susceptibility of recombinant
viruses containing AE-Gag, but not of the reference subtype B strain,
NL4-3
In order to further conﬁrm the role of K165 in reducing viral drug
susceptibility to PIs, we introduced K165 into reference subtype B strain,
as well as to 3 recombinant viruses containing AE-Gag, and subjected
these recombinant viruses to drug susceptibility tests. The results
showed that the introduction of K165 into the reference subtype B strain
did not signiﬁcantly alter viral drug susceptibility to PIs (Fig. 4, compare
NL4-3 Gag and NL4-3 Gag-S165K). In contrast, the introduction of K165
into 3 recombinant viruses, containing AE-Gag5, AE-Gag29 and AE-
Gag60, reduced the drug susceptibility of these recombinant viruses to
several PIs (Fig. 4). These results suggest that K165 reduces the drug
susceptibility of CRF01_AE viruses, but not of the subtype B strain, NL4-3.
Table 1
Amino acid residue at position 165 of HIV-1 Gag.
n N165a K165a S165a
Subtype Ab 100 21% (aac) 0% (nd) 79% (agc)
Subtype Bb 100 2% (aac) 0% (nd) 98% (agc, agt)
Subtype Cb 100 0% (nd) 0% (nd) 100% (agc, agt)
Subtype Db 100 17% (aac, aat) 0% (nd) 83% (agc, agt)
CRF01_AEb 200 98.5% (aac, aat) 1% (aaa) 0.5% (agc)
CRF02_AGb 100 2% (aac, aat) 0% (nd) 98% (agc, agt)
a Frequency (%) of samples with asparagine (N165), lysine (K165) or serine (S165)
residue at amino acid position 165 of Gag was estimated. Genetic codes for amino acid
position 165 detected in the samples are shown in parentheses. nd: not detected.
b 100 gag gene sequences of subtype A, B, C, D or CRF02_AG viruses with sampling
dates 2000–2007, 2006–2007, 2006–2008, 1990–2005 or 1997–2007, respectively, as
well as 200 gag gene sequences of CRF01_AE viruses with sampling dates 1990–2007,
were retrieved from the HIV sequence database (www.hiv.lanl.gov/). The deduced
amino acid sequences were translated and examined. Accession numbers are available
upon request.
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PR (rPR) both in the absence and presence of RTV
PIs abolishes viral infectivity by inhibiting the PR-mediated
proteolytic maturation of HIV-1 Gag. In order to elucidate the
molecular mechanism of how K165 reduced viral drug susceptibility
to PIs, we examined the rPR-mediated in vitro cleavage of Gag
precursor protein, p55, derived from 0.1% NP40-permeabilized PR-
deﬁcient virus. Immunoblot analysis using anti-Gag p17 and anti-Gag
p15 antibodies revealed that p55 was initially cleaved at the p2/p7
cleavage site, leading to the generation of 40 kDa (p40) and 15 kDa
(p15) bands (data not shown). In addition, immunoblot analysis using
anti-Gag p24 antibody showed that p55 gradually cleaved and
disappeared, while p40 and p24 were generated subsequently
(Fig. 5A). The cleavage of Gag was partially inhibited by RTV in a
dose-dependent manner (Figs. 5B and C); however, the extent of the
subsequent cleavage of precursor Gag p55 both in the absence and
presence of RTV was comparable between AE-Gag62 and AE-Gag62-
K165N (Fig. 5), suggesting that K165 had no signiﬁcant effect on the
extent of Gag cleavage or on the inhibitory effect of RTV on rPR-
mediated cleavage of Gag, at least in an in vitro assay.
Analysis of virion-associated proteins
We next examined the impact of K165 on the incorporation of Gag
and Gag–Pol precursor proteins into virions. To this end, immunoblot
analysis of puriﬁed AE-Gag62- and AE-Gag62-K165N-recombinant
viruses as well as of PR-deﬁcient mutants was performed using anti-
Gag p24 antibody, V107,whichwas previously conﬁrmed to speciﬁcally
detect not only Gag p24, but also Gag–Pol and Gag precursor protein,
p160, p55 and p40 (intermediate precursor of p17 and p24) (Ikuta et al.,
1989). The results showed that the extent of Gag incorporation was
comparable between AE-Gag62- and AE-Gag62-K165N-recombinant
viruses (Fig. 6A). In contrast, AE-Gag62-recombinant, PR-deﬁcient virus
contained a higher amount of Gag–Pol precursor protein, p160, thanAE-
Gag62-K165N-recombinant, PR-deﬁcient virus (Fig. 6B), suggesting that
K165 enhanced the incorporation of Gag–Pol precursor protein into
virions. We also tried to detect PR from AE-Gag62- and AE-Gag62-
K165N-recombinant viruses by immunoblot analysis using anti-PR
antibody, but failed to detect it (data not shown). In order to conﬁrm the
impact of K165on the incorporation of Gag–Pol precursor protein, p160,
PR-deﬁcient viruses containing AE-Gag5, AE-Gag5-N165K, NL4-3 Gag
and NL4-3 Gag-S165K were prepared and subjected to immunoblot
analysis. The results showed that a higher amount of p160was detected
in PR-deﬁcient viruses containing AE-Gag5-N165K and NL4-3 Gag-
S165K compared to PR-deﬁcient viruses containing AE-Gag5 and NL4-3
Gag, respectively (Fig. 6C). These results conﬁrmed that K165 enhanced
the incorporation of Gag–Pol precursor protein, p160, into virions.Impact of K165 on the infectivity of recombinant viruses
Finally, we studied the impact of K165 on viral infectivity. A single-
round replication assay revealed that the infectivity of AE-Gag62-
recombinant virus was comparable to that of AE-Gag62-K165N-
recombinantvirus (Fig. 7). In addition, the infectivityof the recombinant
virus containing AE-Gag mutant, AE-Gag5-N165K, AE-Gag29-N165K or
AE-Gag60–N165K, was moderately reduced relative to that of the
recombinant virus containing the correspondingwild-type AE-Gag, AE-
Gag5, AE-Gag29 or AE-Gag60, respectively (Fig. 7). In contrast, the
infectivity of the recombinant virus containing NL4-3 Gag-S165K was
markedly reduced by 96% relative to parental subtype B strain (Fig. 7).
These results suggested that K165 had no effect or moderately reduced
the infectivity of CRF01_AE viruses, whereas it signiﬁcantly reduced the
infectivity of the subtype B strain, NL4-3. Although no correlation was
observed between drug susceptibility and the infectivity of the
recombinant viruses, we considered that the marked reduction in its
infectivity affected the drug susceptibility of the recombinant virus
containing NL4-3 Gag-S165K; therefore, the introduction of K165 into
NL4-3 Gag might not reduce viral drug susceptibility to PIs.
Discussion
In this report, we show that the lysine residue at amino acid
position 165 (K165) of AE-Gag plays a role in reducing the drug
susceptibility of recombinant viruses to PIs. In addition, we propose
that K165 potentially appears more frequently in CRF01_AE viruses
than in the viruses of other major HIV-1 subtypes, although the
mechanism is still unclear. A recent report showed that the N-terminal
region, including p17 and the N-terminus of p24, of subtype A Gag is
responsible for reducing viral drug susceptibility to PIs (Parry et al.,
2009). Their results and ours consistently indicated that the N-
terminal region of non-B subtype Gag played a role in reducing viral
drug susceptibility to PIs.
Previous studies on drug-resistant viruses that appeared in PI-
treated patients (Ho et al., 2008; Mammano et al., 1998; Tamiya et al.,
2004; Zhang et al., 1997) or appeared during in vitro serial passage of a
virus in the presence of PI (Carrillo et al., 1998; Doyon et al., 1996)
revealed that mutations at PR cleavage sites of Gag improve viral
ﬁtness. In addition, mutations at non-cleavage sites of Gag also play a
role in recovering the viral ﬁtness of PI-resistant viruses (Gatanaga et
al., 2002; Myint et al., 2004). In contrast to these reports, our results
showed that K165 had no effect or moderately reduced the infectivity
of AE-Gag-recombinant viruses (Fig. 7), while it reduced the drug
susceptibility of these viruses to PIs (Figs. 3 and 4), indicating clearly
that K165 affects viral drug susceptibility to PIs by a different
mechanism from that of previously reported Gag mutations.
Although K165 is located 33 amino acids downstream of the
17/p24 cleavage site (Fig. 2), we considered that K165 might affect
the structure of the PR cleavage site, leading to improved cleavability
of Gag and/or a reduced inhibitory effect of PI on PR-mediated Gag
cleavage; however, our results showed that K165 had no effect on the
extent of rPR-mediated cleavage of Gag or on the inhibitory effect of
RTV on rPR-mediated Gag cleavage (Fig. 5). In contrast, K165 played a
role in enhancing the incorporation of Gag–Pol precursor protein,
p160, into virions (Fig. 6). Although there is no direct evidence, it is
conceivable that K165 plays a role in increasing the amount of PR in
virions; therefore, the efﬁciency of Gag cleavage is increased, and the
relative inhibitory effect of PIs on Gag cleavage is eventually reduced.
HIV-1 Gag p24 contains two functionally distinctive regions; namely,
the N-terminal region of Gag p24 contains a binding domain for
cyclophilin A (Franke et al., 1994; Luban et al., 1993; Thali et al., 1994),
whereas the C-terminal region of Gag p24 plays an important role in
regulating virion assembly as well as the incorporation of Gag–Pol
precursor protein into virions (Abdurahman et al., 2004; Chazal et al.,
1994; Chien et al., 2006; Huang and Martin, 1997; Mammano et al.,
Fig. 4. The lysine residue at amino acid position 165 (K165) of Gag plays a role in reducing the drug susceptibility of 3 AE-Gag-recombinant viruses, but not of the subtype B reference
strain. K165 was introduced into 3 AE-Gag-recombinant viruses as well as to the reference subtype B strain, as described in Materials and methods. The drug susceptibility of the
recombinant viruses lacking (left panels) or containing K165 (right panels) to 9 PIs was evaluated as described in the ﬁgure legend for Fig. 1. IDs of HIV-1 Gag are shown above the
panels. In addition, 9 PIs used in the tests are indicated below the panels. Results are presented as the means and standard deviations (error bars) of four independent experiments.
Dunnett's t test was performed within a one-way analysis of variance experimental design, and N2.0- or b0.5-fold change in susceptibility to the PI, with a P value of b0.05, was
considered signiﬁcant (*). In addition, themean IC50 valueswith standard deviations of PIs for suppressing the replication of recombinant viruses are shown in Supplementary Table 1.
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of p24 plays a role in regulating the assembly and maturation of
virions (Fitzon et al., 2000). Our results suggest that an amino acidsubstitution, N165K or S165K, might act as a gain-of-function
mutation to increase the incorporation of Gag–Pol precursor protein
into virions. The amino acid residue at position 165 of Gag is located
Fig. 5. K165 has no signiﬁcant effect on rPR-mediated in vitro cleavage of Gag precursor protein, p55, or on the inhibitory effect of RTV on the cleavage of Gag. AE-Gag62- and AE-
Gag62-K165N-recombinant, PR-deﬁcient viruses were puriﬁed andmock-treated (A) or treated with 31 nM (B) or 125 nM of RTV (C) for 5 min. Puriﬁed viruses were then incubated
with rPR at 37 °C, as described in Materials and methods. The reaction was allowed to proceed for 0 (lane 1), 1 (lane 2), 3 (lane 3), 10 (lane 4), 20 (lane 5) and 40 (lane 6) min, and
was then stopped by mixing the sample with sample buffer, immediately followed by heating the sample at 95 °C for 4 min. Viral samples equivalent to 6 ng of p24 antigen were
loaded onto SDS-PAGE gel. Immunoblot analysis using anti-Gag p24 monoclonal antibody was then performed as described in Materials and methods. Arrowheads indicate the
bands corresponding to HIV-1 Gag p55, p40 and p24. The intensities of the p40 and p55 bands were quantiﬁed using ImageJ version 1.43, and the relative ratios between p40 and p55
are shown beside the panels.
135M. Kameoka et al. / Virology 405 (2010) 129–138between helices 1 and 2 of p24, and faces the C-terminal region of p24
in the crystal structure (Gamble et al., 1997; Gitti et al., 1996);
therefore, K165 potentially affects the structure of the C-terminal
region of Gag p24, leading to regulation of the incorporation of Gag–
Pol precursor protein into virions. The mutations introduced into the
proximal region of position 165 of Gag signiﬁcantly affected viral
infectivity (Fitzon et al., 2000). In our study, amino acid substitution at
position 165 markedly reduced the infectivity of the subtype B strain,
NL4-3-derived reporter virus, while such a substitution had no effect
or moderately reduced that of AE-Gag-recombinant viruses (Fig. 7).
These results suggest that Gag of CRF01_AE viruses, but not of NL4-3,
might be able to maintain its physiological functions in the presence
of K165 during the assembly and/or maturation of virions. Introduc-
tion of K165 had no effect on the drug susceptibility of NL4-3-derived
reporter virus (Fig. 4). We considered that this might be due to the
marked reduction of viral infectivity by the introduction of K165.Our study revealed that an amino acid substitution, N165K, in AE-
Gag reduced viral drug susceptibility to PIs. In addition, K165 was
found in 1% of CRF01_AE Gag sequences retrieved from the HIV-1
database; however, no reports have described the appearance of an
amino acid substitution, N165K or S165K, in HIV-1 Gag during the
treatment of HIV-1-infected patients with PIs; thus, it remains unclear
whether K165 really plays a role in the acquisition of drug resistance.
To clarify the impact of K165 on the PI susceptibility of CRF01_AE
viruses, we plan to examine the correlation between the prevalence of
this mutation and the prognosis of PI-treated Thai patients. Limited
data are presently available on PI resistance-associated Gagmutations
of non-B subtypes of HIV-1, including CRF01_AE viruses. We consider
that further studies are required to better understand the impact of
genetic diversity among different subtypes and CRFs on viral drug
susceptibility as well as to establish a drug-resistance database for
non-B subtypes of HIV-1.
136 M. Kameoka et al. / Virology 405 (2010) 129–138Materials and methods
Preparation of recombinant proviral constructs
cDNAs encoding AE-Gag5, AE-Gag29, AE-Gag60 and AE-Gag62were
ampliﬁed from plasma samples #5, #29, #60 and #62, which were
derived from HIV-1-infected, drug treatment-naïve Thai patients,
respectively, and were cloned into a pNL4-3-derived, envelope
protein-deﬁcient, luciferase reporter proviral construct carrying a
cassette site for the insertion of gag and pol genes, pNL-Luc-E−-
gagpolCT (Kitagawaet al., 2008), as describedpreviously (Jinnopat et al.,
2009). The proviral construct, pNL-Luc-E−-gagpolCT, contains a unique
recognition site for BssHII, PvuI, ClaI and XbaI immediately upstream of
the viral gag, protease, reverse transcriptase and integrase genes,
respectively, and for BlpI immediately downstream of the integrase
gene (Kitagawa et al., 2008). In addition, the recognition site for PstI is
located within the gag gene encoding p24. In order to generate the
recombinant proviral construct containing a partial fragment of AE-
Gag62, the BssHII–PstI fragment encoding the N-terminal regions of AE-Fig. 6. K165 has no effect on the incorporation of Gag proteins, but it enhances the incorporat
Gag62 and AE-Gag62-K165N (A) and PR-deﬁcient viruses containing AE-Gag62, AE-Gag62
puriﬁed as described in Materials and methods. Puriﬁed virus was mixed with sample buffer
to 20 ng (lane 1), 10 ng (lane 2), 5 ng (lane 3), 2.5 ng (lane 4), 1.25 ng (lane 5) and 0.625 ng (
monoclonal antibodywas then performed as described inMaterials andmethods. Arrowhead
of the bands in lane 1 were quantiﬁed using ImageJ version 1.43, and the relative amounts (a
p55 (B and C) are shown beside the panels.Gag62 (p17 and a partial sequence of p24, AE-Gag62N) or the PstI–PvuI
fragment encoding the C-terminal regions of AE-Gag62 (a partial
sequence of p24, p2, p7, p1 and p6; AE-Gag62C) was cleaved from AE-
Gag62-recombinant proviral DNA, and then inserted into pNL-Luc-E−-
gagpolCT. The resultant proviral constructs containing the chimeric gag
gene consisted of partial gene fragments of NL4-3 Gag and AE-Gag62. In
addition, a series of Gag mutants containing point mutations, E14D,
K91R/V92I, E110K, K165S, K165N, S165K and N165K, was generated by
site-directed mutagenesis using the QuikChange® site-directed muta-
genesis kit (Stratagene, Cedar Creek, TX).Moreover, in order to generate
PR-deﬁcient viruses, the PvuI–ClaI gene fragment encoding PR of the
recombinant proviral constructs was replaced with a 96 base-pair
linker, which was prepared by annealing two oligonucleotides, 5′-
CGACAAGGAACTGTATCCTTTAGCTTCCCTCAGATCACTCTTTGGCAGC-
GACCCCTCGTCACAATATGCACTTTAAATTTTCCCATTAGTCCTAT-3′ and
5 ′-CGATAGGACTAATGGGAAAATTTAAAGTGCATATTGTGAC-
GAGGGGTCGCTGCCAAAGAGTGATCTGAGGGAAGCTAAAGGATA-
CAGTTCCTTGTCGAT-3′. The resultant proviral constructs express a
truncated form (lacking amino acid residues 14 to 94) of NL4-3 PR.ion of Gag–Pol precursor protein, p160, into virions. Recombinant viruses containing AE-
-N165K, AE-Gag5, AE-Gag5-N165K, NL4-3 Gag, and NL4-3 Gag-S165K (B and C) were
, heated at 95 °C for 4 min, and was then 2-fold serially diluted. Viral samples equivalent
lane 6) of p24 were loaded onto SDS-PAGE gel. Immunoblot analysis using anti-Gag p24
s indicate the bands corresponding to HIV-1 Gag p160, p55, p40 and p24. The intensities
rbitrary intensity) of Gag p55, p40 and p24 (A) or the relative ratios between p160 and
Fig. 7. K165 has no effect or moderately reduces the infectivity of AE-Gag-recombinant
viruses, while it markedly reduces that of the recombinant virus containing NL4-3 Gag.
Viral infectivity of recombinant viruses containing K165 (closed bar, K165) was
compared with that of recombinant viruses lacking K165 (open bars, N/S165), as
described in Materials and methods. Data are shown as the fold difference in luciferase
activity produced by the virus containing K165 relative to luciferase activity produced
by the virus lacking K165. Results are presented as the means and standard errors
(error bars) of three independent experiments. Differences among viruses were
analyzed by the paired t test, and are reported when Pb0.05.
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The amino acid sequences of AE-Gag5 (GenBank accession no.
EU787509), AE-Gag29 (EU787510), AE-Gag60 (EU787515), AE-Gag62
(EU787516) and a reference CRF01_AE strain, CM240 (U54771) were
translated from the nucleotide sequences and aligned with that of
NL4-3 (AF324493), using the ClustalW algorithm (Thompson et al.,
1994) with slight manual adjustment.
PIs
APV, ATV, DRV (provided by Tibotec, Inc.), IDV, LPV, NFV, RTV, SQV
and TPV were obtained through the NIH AIDS Research and Reference
Reagent Program (ARRRP) (Division of AIDS, NIAID, NIH).
Drug susceptibility test
Drug susceptibility tests were carried out as described previously
(Jinnopat et al., 2009). Brieﬂy, 293T cells (3×106 cells in 100 mmdish)
were transfectedwith 17.7 μg recombinant proviral construct together
with 2.3 μg vesicular stomatitis virus G protein (VSVG) expression
plasmid, pHit/G (Fouchier et al., 1998), using FuGENE HD transfection
reagent (Roche, Basel, Switzerland), to generate VSVG-pseudotyped
HIV-1. Seventeen hours later, the transfected 293T cells were
trypsinized and split into 200 μl subcultures in a 96-well plate in the
presence of various concentrations of PIs (3.125 to 400 nM for APV,
0.125 to 16 nM for ATV, 0.094 to 6 nM for DRV, 1.25 to 160 nM for IDV,
1.563 to 100 nM for LPV, 1.25 to 80 nM for NFV, 2.5 to 640 nM for RTV,
0.375 to 24 nM for SQV and 20 to 640 nM for TPV). After 31 h of PI
treatment, the cell culture supernatantwas used to infect subconﬂuent
293T cells in a 96-well plate. Twenty-four hours after infection,
luciferase activity in infected cells was measured using the Steady Glo
Luciferase assay kit (Promega,Madison,WI)with an LB960microplate
luminometer (Berthold, Bad Wildbad, Germany). Drug susceptibility
was evaluated as a reduction in luciferase activity in infected cells. The
50% inhibitory concentration (IC50) of PIs for suppressing viral
replication was calculated by the dose–response curve using a
standard function of GraphPad Prism 5 software (GraphPad Software,
San Diego, CA). Independent experiments were performed four times.
Dunnett's t test was then performed within a one-way analysis of
variance experimental design. Results are expressed as the fold change
in susceptibility to PI, which was calculated as the ratio of the mean
IC50 value for the recombinant virus to themean IC50 value forNL-Luc,which was generated from the proviral construct, pNL-Luc-E−-
gagpolCT, and used as the reference subtype B strain in this study.
More than 2.0- or less than 0.5-fold change in susceptibility to the PI,
with a P value of b0.05, was considered signiﬁcant.
Viral infectivity assay
The level of single-round replication of recombinant viruses was
examined, as follows. 293T cells, which were seeded onto a 24-well
plate (6×104 cells per 500 μl per well) 24 h prior to transfection, were
transfected with 590 ng recombinant proviral construct together with
78 ng pHit/G using FuGENE HD transfection reagent (Roche). Forty-
eight hours after transfection, viral supernatants were centrifuged at
8000 rpm for 5 min. 293T cells, which were seeded onto a 24-well
plate (3×104 cells per 500 μl per well) 24 h prior to the tests, were
then incubated with a 200-μl aliquot of viral supernatants. Forty-eight
hours after infection, luciferase activity in infected cells wasmeasured
as described above. Relative infectivity was calculated by dividing
luciferase activity produced by the recombinant virus containing K165
by that produced by the virus lacking K165. Statistical analysis was
carried out using the standard function of GraphPad Prism 5 software
(GraphPad Software) with a paired t test.
Preparation of recombinant PR (rPR)
A synthetic gene fragment encoding NL4-3 PR, which was
optimized to the codon bias of the Escherichia coli gene (GeneOpti-
mizer® sequence optimization; GENEART AG, Regensburg, Germany),
was cloned into pQE-30 (Qiagen, Hilden, Germany). Six-histidine-
tagged rPR was puriﬁed under denaturing conditions using Ni-NTA
agarose (Qiagen), essentially as described previously (Kameoka et al.,
1999). Puriﬁed rPR was dialyzed against 20% glycerol–phosphate-
buffered serine (PBS), and stored as aliquots at −85 °C.
In vitro reaction for rPR-mediated cleavage of Gag
PR-deﬁcient virus was prepared by transfecting 293T cells with the
proviral construct, as described above. Viral particles in the culture
supernatants were puriﬁed by centrifugation though a 15-ml cushion
of 20% (W/V) sucrose in PBS at 130,000×g for 2 h at 4 °C using an
SW32Ti rotor with an Optima L-90K ultracentrifuge (Beckman
Coulter, Fullerton, CA). Precipitates were resuspended in 100 mM
sodium acetate, pH 5.4. The concentration of HIV-1 Gag p24 antigen in
the sample was measured by enzyme-linked immunosorbent assay
(ELISA) (BioAcademia, Osaka, Japan) following the incubation of a
small aliquot of sample with 2 μg rPR for 1 h, essentially as described
below. This method enabled us to quantify PR-deﬁcient viruses.
In order to evaluate rPR-mediated cleavage of the Gag precursor
protein, p55, viral particles (84 ng of p24) were incubated with rPR
(1.8 μg) in the reaction buffer [100 mMsodium acetate, pH5.4, 100 mM
sodium chloride, 1 mMdithiothreitol, 0.1% TritonX-100, and 100 μg/ml
bovine serum albumin] at 37 °C for the indicated time periods. The
reaction was then stopped by mixing a sample with sample buffer
[62.5 mM Tris–HCl, pH 6.8, 2% sodium dodecylsulfate (SDS), 10%
glycerol, 5% 2-mercaptoethanol, 0.003% bromophenol blue and com-
plete protease inhibitor cocktail (Roche)], immediately followed by
heating samples at 95 °C for 4 min. The level of Gag cleavage was then
evaluated by immunoblot analysis, as described below.
Immunoblot analysis of viral proteins
Samples were separated by SDS-polyacrylamide gel electrophore-
sis (SDS-PAGE) and transferred to a polyvinylidene ﬂuoride mem-
brane. After blocking with 5% non-fat milk in PBS, the blots were
immunostained with anti-Gag p24 (V107) monoclonal antibody,
which recognizes mature HIV-1 capsid protein, p24, as well as Gag–
138 M. Kameoka et al. / Virology 405 (2010) 129–138Pol and Gag precursor proteins, p160, p55 and p40 (intermediate
precursor of p17 and p24) (Ikuta et al., 1989), anti-Gag p17 polyclonal
antibody, which recognizes mature HIV-1 matrix protein, p17, and
Gag precursor protein, p55 (provided by Dr. Paul Spearman through
ARRRP) (Varthakavi et al., 1999), anti-Gag p15 polyclonal antibody,
which recognizes Gag precursor proteins, p55 and p15 (intermediate
precursor of p7, p1 and p6) (BioAcademia) or anti-HIV-1SF2 PR
polyclonal antibody (provided by BioMolecular Technology through
ARRRP). After incubation of the samples with peroxidase-labeled
secondary antibodies, the immuno-complex was visualized using ECL
plus™ Western blotting detection reagents (Amersham Pharmacia
Biotech, Uppsala, Sweden). ECL plus-exposed ﬁlms were scanned and
the intensities of the bands were quantiﬁed using ImageJ version 1.43
(Rasband, W. S., ImageJ; U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/).
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